Belize vs Iraq: HIV/AIDS deaths averted by antiretroviral therapy
Belize
87.27 deaths
in 2024
Iraq
77.64 deaths
in 2024
Belize rank
127th
Iraq rank
130th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Belize
- Iraq
How they compare
Belize currently reports 87.27 deaths against 77.64 deaths in Iraq, a difference of 9.63 deaths.
That makes Belize's figure about 1.1 times Iraq's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Iraq ahead.
Belize ranks 127th and Iraq ranks 130th of 157 countries.
Belize has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Belize | Iraq | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 40.13 deaths | 12.75 deaths | 27.38 deaths | Belize |
| 2010s | 94.11 deaths | 17.01 deaths | 77.11 deaths | Belize |
| 2020s | 74.23 deaths | 54.96 deaths | 19.27 deaths | Belize |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Belize or Iraq?
- Belize, at 87.27 deaths against 77.64 deaths in Iraq as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Belize and Iraq?
- 9.63 deaths, with Belize ahead.
- How many years of comparable data are there for Belize and Iraq?
- 35 years are reported by both, from 1990 to 2024.
- How do Belize and Iraq rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Belize ranks 127th and Iraq ranks 130th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.